Last updated: March 27, 2026
What is NDC 68462-0713?
National Drug Code (NDC) 68462-0713 corresponds to Xywav, a calcium, magnesium, and sodium oxybates oral solution. It is approved for the treatment of narcolepsy and idiopathic hypersomnia. Xywav is a reformulation of sodium oxybate (approved as XYREM), with a lower sodium content designed to reduce cardiovascular risks.
Market Overview
Regulatory Status
- Approved by the FDA in December 2020.
- Licensed for narcolepsy and idiopathic hypersomnia.
- Marketed predominantly through Jazz Pharmaceuticals, which acquired it from Eton Pharmaceuticals.
Indications
- Narcolepsy: Excessive daytime sleepiness and cataplexy.
- Idiopathic hypersomnia: Severe sleepiness with difficulty waking.
Competitors
- Sodium oxybate (XYREM): Same active compound, higher sodium content.
- Stimulants: Modafinil, armodafinil.
- Adrenergic agents: Atomoxetine.
- Off-label therapies: Various sleep aids.
Market Size
- Estimated global narcolepsy market: $300–400 million (2022).
- U.S. market for narcolepsy drugs: Approximately $270 million in 2022.
- Rise in diagnosis rates and awareness increases market penetration.
Patient Population
- U.S. narcolepsy prevalence: 25–50 per 100,000.
- Estimated U.S. patients: ~150,000.
- Idiopathic hypersomnia: Less understood, but estimated at similar prevalence rates of 10–15 per 100,000.
Pricing and Revenue
- List Price (2023): ~$17,000 per month.
- Average Wholesale Price (AWP): ~$16,500–$17,500 monthly.
- Estimated annual revenue (2023): $200–$250 million, driven by U.S. sales.
Market Penetration
- Jazz Pharmaceuticals holds significant market share due to extensive marketing and clinician awareness.
- Insurance coverage is critical for patient access, affecting net sales.
Price Projections
Short-Term (Next 1-2 Years)
- Stable pricing influenced by high manufacturing costs and patents expiring in 2027.
- Slight price increases: 2-3% annually, aligned with inflation and market demand.
- Insurance negotiations could pressure prices downward, especially with increased competition.
Medium-Term (3-5 Years)
- Potential generic entry expected post-2027, given patent expiration.
- Price decline forecasts: 20-30% over five years, driven by generics and biosimilar-like competition.
- Value-based pricing may emerge if efficacy data supports differentiated positioning.
Long-Term (Beyond 5 Years)
- Post-generic competition:
- Entry of lower-cost formulations or biosimilars.
- Price erosion: 40-50% from peak levels.
- Market dynamics could shift if new therapies for narcolepsy (e.g., novel orexin agonists) gain approval and market share.
Key Factors Affecting Pricing
- Patent lifecycle: Expiring in 2027.
- Competition: Entry of generics reduces prices.
- Regulatory changes: Any reform on narcotic scheduling impacting production.
- Reimbursement policies: Insurance coverage influences net prices.
- Clinical advancements: Better therapies could diminish reliance on oxybate formulations.
Future Market Drivers
- Increased diagnosis rates.
- Expanded indications (e.g., shift toward use in pediatric populations).
- Accessibility improvements through insurance coverage.
- New formulations enhancing compliance or reducing side effects.
Risks and Uncertainties
- Patent litigation or delays.
- Accelerated generic approvals.
- Off-label use of competing drugs.
- Reimbursement reforms impacting profitability.
Key Takeaways
- NDC 68462-0713 (Xywav) targets a niche but growing sleep disorder market.
- Current US list prices are ~$17,000/month, with revenues around $200–$250M annually.
- Price pressures expected after patent expiry in 2027, with significant declines forecasted over five years.
- Market dominance by Jazz Pharmaceuticals likely sustains current prices until generics erode market share.
- The development of new therapies and changes in reimbursement will influence long-term market dynamics.
FAQs
1. When will generic competition for Xywav likely begin?
Post-2027, based on patent expiry, with potential for generic versions entering the market.
2. How does the pricing of Xywav compare to XYREM?
Xywav's list price is similar to XYREM but marketed at a slightly lower cost due to its reduced sodium content.
3. What is the impact of insurance coverage on Xywav's market?
Coverage determines patient access; better reimbursement supports higher sales and price stability.
4. Are there key patent protections beyond 2027?
Main patent protection expires in 2027; additional patents might offer supplementary protections but are not expected to extend significantly.
5. How might new therapies influence the market over the next decade?
Innovative treatments could reduce reliance on oxybate therapies, leading to lower prices and market share shifts.
References
- Food and Drug Administration. (2020). FDA approves Xywav for narcolepsy and idiopathic hypersomnia. https://www.fda.gov/news-events/press-announcements/fda-approves-xywav-narcolepsy-and-idiopathic-hypersomnia
- IQVIA. (2022). U.S. pharmaceutical market data.
- Industry estimates. (2022). Narcolepsy market size and growth projections.
- Jazz Pharmaceuticals. (2023). Xywav prescribing information.
- U.S. Patent and Trademark Office. (2022). Patent filings related to oxybate formulations.
Note: All price and market size estimates are approximate and subject to change depending on regulatory and market developments.
